All In Biotech

Drug Trial Radar · NCT05363384

A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 25 mg and MET XR 1,000 mg) in Healthy Volunteers

A Randomized, Open, Single-dose, Crossover-design, Phase I Study to Evaluate Bioequivalence After Co-administration of ALO 25 mg and MET XR 1,000 mg or Administration of CT-L01 25/1,000 mg in Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Jan 12, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

48

Actual

Start

Jun 11, 2022

Primary completion

Jun 21, 2022

Study completion Jul 12, 2022

Sponsor

Lead sponsor
CelltrionIndustry
Sponsor type
Industry
First posted
May 5, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a randomized, open, single-dose, crossover-design, phase 1, single-center study to evaluate bioequivalence after co-administration of ALO and MET XR or administration of CT-L01 in healthy volunteers.

Conditions

  • Healthy

Interventions

  • CT-L01Drug

    FDC tablet, single dose, oral administration

  • Alogliptin Benzoate 25 mgDrug

    Alogliptin Benzoate 25 mg, oral administration

  • Metformin HCl XR 1,000 mgDrug

    Metformin HCl XR 1,000 mg, oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AUClast (Area under the plasma concentration-time curve)Time frame: Pre-dose(0.00), 0.25, 0.50, 1.00, 1.50, 2.00, 2.50, 3.00, 4.00, 5.00, 6.00, 7.00, 8.00, 10.00, 12.00, 16.00, 24.00, 36.00, 48.00, and 72.00 hours
  2. Cmax (Peak Plasma Concentration)Time frame: Pre-dose(0.00), 0.25, 0.50, 1.00, 1.50, 2.00, 2.50, 3.00, 4.00, 5.00, 6.00, 7.00, 8.00, 10.00, 12.00, 16.00, 24.00, 36.00, 48.00, and 72.00 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Chungnam National University Hospital

    Daejeon, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.